Primary Investigator: Richard Weachter, MD
Study Coordinator: Kathy Belew, CNS-BC
Status: Closed to entrollment - follow-up continues
Study Title: Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (AF)
Purpose: To determine if apixaban is noninferior to warfarin (INR target range 2.0 - 3.0) in the combined endpoint of stroke (ischemic or hemorrhagic or of unspecified type) and systemic embolism, in subjects with AF and at least one additional risk factor for stroke.
Call Kathy Belew (beeper 573-499-8063) and/or on-call research nurse (on-call beeper 573-499-8084) or Dr. Weachter if subject is admitted to the hospital or for any questions regarding study medication.